Product Information
AMITIZA 24 MCG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $5.9498 per EA under NDC 64764024060. Its NADAC has been published 638 times since Nov 28, 2013.
FDA first approved this application on Jan 31, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lubiprostone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
24 ug/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
64764024060
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
2/19/2025
Active Ingredients
LUBIPROSTONEApproval Type
New Drug (NDA)
FDA Application
NDA021908FDA Approved
1/31/2006
TE Code
AB
On Market Since
1/31/2006
Pharmacological Classes
Price Statistics
The NADAC for AMITIZA 24 MCG CAPSULE has been published 638 times since Nov 28, 2013, and over the history we have for it it has risen 33.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.9498 per EA |
|---|---|
| All-time high | $5.9498 (Feb 11, 2026) |
| All-time low | $4.4519 (Nov 28, 2013) |
| 52-week high | $5.9498 |
| 52-week low | $5.9498 |
| Median price | $5.9330 |
| Average price | $5.6756 |
| Largest weekly change | +9.0% (Apr 9, 2014) |
| Weeks tracked | 638 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
+0.3%
5Y
+0.2%
All
+33.6%
Last surveyed Feb 11, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of AMITIZA 24 MCG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for AMITIZA 24 MCG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $5.9498 per EA (NDC 64764024060), effective Feb 11, 2026.
How has the price of AMITIZA 24 MCG CAPSULE changed over time?
Over the history we have for it, the NADAC for AMITIZA 24 MCG CAPSULE has risen 33.6%. It has been tracked across 638 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AMITIZA 24 MCG CAPSULE?
Since Nov 28, 2013, the NADAC for AMITIZA 24 MCG CAPSULE has ranged from a low of $4.4519 (Nov 28, 2013) to a high of $5.9498 (Feb 11, 2026), with a median of $5.9330 per EA.
Are there cheaper alternatives to AMITIZA 24 MCG CAPSULE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LUBIPROSTONE 24 MCG CAPSULE, is $0.6239 per EA — about 90% below AMITIZA 24 MCG CAPSULE.
Who manufactures AMITIZA 24 MCG CAPSULE?
AMITIZA 24 MCG CAPSULE (NDC 64764024060) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.